Figure 3.

Twist plays an important role in the migratory function of TRAMP-C2 cells and enzalutamide mediates immunogenic modulation. A, expression of Twist was analyzed by RT-PCR in TRAMP-C2 cells transiently transfected with Twist or control siRNAs. B, In vitro cell migration assay was performed using the transiently transfected cells. C, enzalutamide improved TRAMP-C2 cells sensitivity to gp70-specific CD8⁺-cytotoxic T-cell lysis. TRAMP-C2 cells were exposed in vitro to either vehicle (DMSO) or 10 µM enzalutamide for 48 h. Cells were harvested, washed, and labeled with ¹¹¹In. The sensitivity of TRAMP-C2 target cells to gp70-specific killing was determined after cells were incubated at an effector:target ratio of 50:1. D, enzalutamide mediated increase expression of cell surface Fas and MHC-I molecules on TRAMP-C2 cells. TRAMP-C2 tumor cells were treated in vitro for 48 hr with vehicle (open histogram) or 10 µM enzalutamide (shaded histogram) and were analyzed for surface expression Fas and MHC-I by flow cytometry. Numbers in parentheses indicate percentage of positive cells and Mean Fluorescence Intensity. Data is representative of two independent experiments. Statistical analyses were done by Student’s t-test. Error bars indicate mean ± S.E.M. from triplicate measurements.